418 related articles for article (PubMed ID: 26966281)
1. The High-Density Lipoprotein Puzzle: Why Classic Epidemiology, Genetic Epidemiology, and Clinical Trials Conflict?
Rosenson RS
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):777-82. PubMed ID: 26966281
[TBL] [Abstract][Full Text] [Related]
2. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
Kones R
Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
[TBL] [Abstract][Full Text] [Related]
3. Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.
Ronsein GE; Hutchins PM; Isquith D; Vaisar T; Zhao XQ; Heinecke JW
Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):404-11. PubMed ID: 26681752
[TBL] [Abstract][Full Text] [Related]
4. Should low high-density lipoprotein cholesterol (HDL-C) be treated?
Toth PP; Barylski M; Nikolic D; Rizzo M; Montalto G; Banach M
Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):353-68. PubMed ID: 24840264
[TBL] [Abstract][Full Text] [Related]
5. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
[TBL] [Abstract][Full Text] [Related]
6. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
7. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
[TBL] [Abstract][Full Text] [Related]
8. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
9. Residual risk and high-density lipoprotein cholesterol levels: is there a relationship?
Shah PK
Rev Cardiovasc Med; 2011; 12(2):e55-9. PubMed ID: 21796083
[TBL] [Abstract][Full Text] [Related]
10. Triglyceride-rich lipoproteins and HDL: what do recent trials tell us?
Stock J
Atherosclerosis; 2013 Jun; 228(2):329-31. PubMed ID: 23623013
[No Abstract] [Full Text] [Related]
11. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
[TBL] [Abstract][Full Text] [Related]
12. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
[TBL] [Abstract][Full Text] [Related]
13. CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both.
Nicholls SJ
Clin Pharmacol Ther; 2018 Aug; 104(2):297-300. PubMed ID: 29901215
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.
Posadas-Sánchez R; Posadas-Romero C; Mendoza-Pérez E; Caracas-Portilla NA; Cardoso-Saldaña G; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG
Am J Cardiol; 2012 Mar; 109(5):636-41. PubMed ID: 22169129
[TBL] [Abstract][Full Text] [Related]
15. SCARB1 Gene Variants Are Associated With the Phenotype of Combined High High-Density Lipoprotein Cholesterol and High Lipoprotein (a).
Yang X; Sethi A; Yanek LR; Knapper C; Nordestgaard BG; Tybjærg-Hansen A; Becker DM; Mathias RA; Remaley AT; Becker LC
Circ Cardiovasc Genet; 2016 Oct; 9(5):408-418. PubMed ID: 27651445
[TBL] [Abstract][Full Text] [Related]
16. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
17. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.
Lawler PR; Akinkuolie AO; Chu AY; Shah SH; Kraus WE; Craig D; Padmanabhan L; Glynn RJ; Ridker PM; Chasman DI; Mora S
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28733430
[TBL] [Abstract][Full Text] [Related]
18. HDL cholesterol and cardiovascular outcomes: what is the evidence?
Rubenfire M; Brook RD
Curr Cardiol Rep; 2013 Apr; 15(4):349. PubMed ID: 23420445
[TBL] [Abstract][Full Text] [Related]
19. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
20. High-density Lipoprotein (HDL) Dysfunction and the Future of HDL.
Ertek S
Curr Vasc Pharmacol; 2018; 16(5):490-498. PubMed ID: 29149817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
